Morgan Stanley Maintains Overweight on Regeneron Pharmaceuticals, Lowers Price Target to $1184
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Overweight rating on Regeneron Pharmaceuticals but has lowered the price target from $1235 to $1184.
November 01, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on Regeneron Pharmaceuticals but has lowered the price target from $1235 to $1184.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in valuation. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100